Vitamins and mineralsHigh-dose vitamin C — a treatment you won’t hear about at the doctor’s office?
- Andrzej Frydrychowski — Witamina C w postaci liposomalnej
- Jerzy Zięba — Przegląd doniesień na temat witaminy C Jerzy Zięba
- Jerzy Zięba — C – witamina ciężkiej wagi
- Andrzej Frydrychowski — Czego jeszcze nie wiemy o witaminie C? Część 3
- A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. · Redox Biol 2024
- Intravenous vitamin C as micronutrient therapy in patients with sepsis or septic shock: an updated systematic review and meta-analysis of randomized controlled trials. · Front Nutr 2026
- High-dose vitamin C enhances cancer immunotherapy. · Sci Transl Med 2020
- Effect of High-Dose Vitamin C on Tendon Cell Degeneration-An In Vitro Study. · Int J Mol Sci 2024
- Orthomolecular Medicine News Service — A Hallmark of Covid-19: Cytokine Storm/Oxidative Stress and its Integrative Mechanism
- Orthomolecular Medicine News Service — Rationale for Vitamin C Treatment of COVID-19 and Other Viruses
- Orthomolecular Medicine News Service — Published Research and Articles on Vitamin C as a Consideration for Pneumonia, Lung Infections, and the Novel Coronavirus (SARS-CoV-2/COVID-19)
Andrzej Frydrychowski recommended 2 g of vitamin C every three hours and, in life-threatening situations, intravenous doses of 40–200 g per day.
- At the same time, he claimed that intravenous administration at these doses is prohibited.
- Jerzy Zięba described high doses as possible support for severe infections, but stressed that vitamin C does not cure them.
- For kidney problems, he recommended cautious use under a doctor’s supervision.
What the authors write
For a life-threatening infection, the passage recommends intravenous vitamin C doses of 40 to 200 g per day and claims that administering it this way is prohibited.
High doses of vitamin C are presented as possible support in severe viral respiratory infections.
High-dose vitamin C is presented as possible immune support that may limit complications and shorten the course of a viral infection.
During an infection, the passage recommends 2 g of vitamin C every three hours and intravenous administration in life-threatening situations.
High intravenous doses are described as promising for treating COVID-19, but it is also stated that vitamin C does not cure it.
For kidney problems, the passage recommends using vitamin C cautiously and slowly, preferably under a doctor’s supervision.
The passage cites claims about intravenous vitamin C being used to treat several infections, including a 1 g dose for malaria.
Intravenous vitamin C given together with chemotherapy was described in nine patients with advanced pancreatic cancer.
Research from PubMed · Europe PMC
We selected 4 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 751.
In a small randomized trial, adding intravenous vitamin C at a dose of 75 g three times a week to chemotherapy was associated with longer survival and progression-free time in pancreatic cancer.
Aim of the study: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival. Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin C) has shown promise as an adjunct to chemotherapy. We hypothesized adding P-AscH- to gemcitabine and nab-paclitaxel would increase survival in patients with metastatic PDAC.
Results: Intravenous P-AscH- increased serum ascorbate levels from micromolar to millimolar levels. P-AscH- added to the gemcitabine + nab-paclitaxel (ASC) increased overall survival to 16 months compared to 8.3 months with gemcitabine + nab-paclitaxel (SOC) (HR = 0.46; 90 % CI 0.23, 0.92; p = 0.030). Median progression free survival was 6.2 (ASC) vs. 3.9 months (SOC) (HR = 0.43; 90 % CI 0.20, 0.92; p = 0.029). Adding P-AscH- did not negatively impact quality of life or increase the frequency or severity of adverse events. P-AscH- infusions of 75 g three times weekly in patients with metastatic pancreatic cancer prolongs overall and progression free survival without detriment to quality of life or added toxicity (ClinicalTrials.gov number NCT02905578).
“Not stated” does not mean nobody paid — the database does not always record it.
A meta-analysis of studies in patients with sepsis found that intravenous vitamin C was associated with lower 28-day mortality, shorter use of blood pressure-raising drugs, and a greater decrease in SOFA score, although the quality of the evidence was low.
Aim of the study: The adjunctive therapeutic value of vitamin C in sepsis or septic shock patients remains controversial. This study aimed to evaluate the therapeutic efficacy and safety of intravenous administration of vitamin C in sepsis or septic shock patients through meta-analysis.
Results: Fourteen randomized controlled trials enrolling 1,958 patients were eligible for assessment. Meta-analysis demonstrated that intravenous vitamin C reduced 28-day mortality in sepsis or septic shock patients compared to the control group (RR 0.70; 95% CI 0.53 to 0.93; P = 0.02; I 2 = 52%), based on low quality of evidence, and subgroup analysis showed the benefit was driven by single-center studies, not observed in multicenter trials. Vitamin C shortened the duration of vasopressor use (SMD = -0.42, 95% CI -0.77 to -0.08, P = 0.02) and was associated with a greater reduction in SOFA score (MD = -1.04, 95% CI -1.83 to -0.25, P = 0.01), but did not reduce vasopressor dose, length of stay, or 24-h urine output. No significant adverse events were reported. This meta-analysis suggests that intravenous vitamin C might be associated with reduced mortality in sepsis, but the benefit was not confirmed in low-risk-of-bias multicenter trials and was primarily driven by single-center studies.
“Not stated” does not mean nobody paid — the database does not always record it.
In mouse models, high doses of vitamin C slowed tumor growth and strengthened the effects of immunotherapy.
Aim of the study: Vitamin C (VitC) is known to directly impair cancer cell growth in preclinical models, but there is little clinical evidence on its antitumoral efficacy. In addition, whether and how VitC modulates anticancer immune responses is mostly unknown.
Results: High-dose VitC modulates infiltration of the tumor microenvironment by cells of the immune system and delays cancer growth in a T cell-dependent manner. VitC not only enhances the cytotoxic activity of adoptively transferred CD8 T cells but also cooperates with immune checkpoint therapy (ICT) in several cancer types. Combination of VitC and ICT can be curative in models of mismatch repair-deficient tumors with high mutational burden. This work provides a rationale for clinical trials combining ICT with high doses of VitC.
“Not stated” does not mean nobody paid — the database does not always record it.
In a laboratory study of tendon cells, a high dose of vitamin C limited cell death and damage.
Aim of the study: Tendinopathy is an aging-related disease, often caused by micro-scarring and degeneration due to overuse or trauma. Ascorbic acid (vitamin C) supplementation is reported to be a useful treatment for tendinopathy recovery.
Results: The cytoskeleton was maintained in the HC group but not in the C group. qPCR analysis revealed that p16 expression was inhibited in both the C and HC groups compared to the H2O2 group; other markers had increased expression. The progression of cell death and cytoskeletal disruption was inhibited by the administration of high-dose vitamin C. Hence, high-dose vitamin C is a potential treatment for tendon cell degeneration.
“Not stated” does not mean nobody paid — the database does not always record it.
Perspectives and opinion materials
The content below presents the authors’ opinions, interpretations and hypotheses. It is not treated as equal to scientific studies and systematic reviews.
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.